Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Adam Mead

PhD FRCP FRCPath


Professor of Haematology

  • Consultant Physician
  • CRUK Senior Cancer Research Fellow

Normal and malignant haematopoietic stem cell biology

Normal and malignant haematopoietic stem cell biology

I trained in medicine and haematology at the University of Oxford and UCL and completed my PhD at UCL in 2007. I am currently funded by a CRUK Senior Cancer Research Fellowship.

The overarching focus of my research group is to characterise genetic and cellular heterogeneity in myeloproliferative neoplasms (MPN) and related myeloid neoplasms with the ultimate goal to improve the diagnosis, risk-stratification and treatment of these largely incurable forms of blood cancer. Our work using cutting edge techniques in single cell genomics and in vivo models has revealed hitherto unrecognised heterogeneity of cancer stem cells, including a key role for inflammation in promoting therapy resistance and genetic evolution. Understanding the interplay between genetic, metabolic and inflammatory factors in the clonal evolution of myeloid malignancies is now the key focus of my research group.

My research is closely linked with my clinical practice based at Oxford University Hospitals NHS Trust where I am myeloid clinical lead. I am or have been the principal/chief investigator for over 50 trials. I led the development of JAK2 inhibitor therapies in the UK for patients with MPN as chief investigator, scientific lead or co-investigator on multiple key clinical trials (ROBUST, MAJIC, MITHRIDATE, PERSIST-1 and -2, MPDRC114, PHAZAR, PAC203, FEDORA, PROMise).